Photo Gallery
Photos from April 2019 are now available to download and share - view the full photo gallery here.
Why Attend
The animal health industry is changing. Since the Zoetis spin-out from Pfizer we’ve seen further companies such as Elanco follow suit with successful IPO’s.
Investors are beginning to take notice, however questions still remain regarding the opportunities in the industry:
- What does animal health really offer investors when compared to human health?
- In what ways can human biotech’s leverage the space to maximize their own technology?
Our investor conference in Boston will answer these questions and bring together domain experts and market leading companies to present the current trends and dynamics of the animal health industry and to outline where capital investment can make an impact.
Animal Health has distinct advantages over human healthcare:
- The research and development process for animal health products is typically shorter and less expensive than for human therapeutics, as animal trials typically can be performed in the target species at an earlier stage, and shorter lifespans result in faster safety assessment and trial completion.
- A substantial portion of animal health R&D is focused on product life-cycle management as opposed to novel drugs, which also leads to less risky pipelines.
- Animal health medicines and vaccines face lower pressure from generic competition when compared to human healthcare peers.
- Animal health is primarily a cash business and does not face the same insurance/third party payer and drug pricing risks that can be an overhang on human therapeutics.
Animal health is leveraging clear and present opportunities:
Speakers & Investor Retreat Participants
Aaron Schacht
Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Charles Hoare
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
George Gunn
Justine Conway
John W. Dombrosky
John W. Dombrosky serves as Chief Executive Officer (CEO) of Agtech Accelerator. Launched in 2016 with a consortium of leading venture and industry strategic investors, Agtech Accelerator identifies, forms, capitalizes, and builds from scratch the most promising early-stage agricultural technology companies. The Agtech Accelerator team exclusively focuses on series seed to series a company creation across the ag and food tech economic value system.
Prior to joining Agtech Accelerator, Mr. Dombrosky spent eight years at Syngenta, where his responsibilities spanned licensing, mergers and acquisitions, strategic planning, and business unit leadership roles. In addition to his experience in the agriculture sector, Mr. Dombrosky developed a deep understanding of software and value-added information platforms at Thomson Reuters while serving in finance, business development, and mergers & acquisition roles. Fostering his lifelong fascination with speed and flight, Mr. Dombrosky’s first professional job was as a corporate planning analyst at northwest airlines.
Mr. Dombrosky earned a Bachelor of Arts in financial management from the University of St. Thomas and an MBA from the University of Notre Dame.
Michelle Haven
Rimma Driscoll
Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.
Jarne Ellenholm
Jarne Elleholm, Managing Partner, has more than 20 years’ experience in the life science industry with a strong record of achievements in commercialization and fundraising of life science products and companies.
He has worked in the venture capital industry as partner in Vækstfonden and as Managing Partner in Inventure Capital. From 2005-07 he served as CEO of the biotech company Aresa A/S, where he built up the organization and completed an IPO raising more than DKK 50 million.
Prior experience includes European Vice President for Whatman International and CEO for Lundbeck Ltd. UK where he successfully launched several pharmaceutical products.
Jarne Elleholm served as Chairman of the board of Scandinavian Micro Biodevices and was pivotal in the sale of the company to Zoetis in 2016.
Jarne holds an M.Com from Copenhagen Business School and an MBA from INSEAD.
Rob Readnour
Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies, Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets, and Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health.
Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). In 2017, these new business areas accounted for nearly 50% of Elanco’s $3.0 billion in sales. Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.
Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.
Sébastien Lafon
Sam Al-Murrani
Babylon BioConsulting LLC is a human and animal health-based consultancy firm specializing in pre-revenue and early stage valuations of Animal Health and Biotech companies and providing clients with investor outreach, due diligence, business development and intangible asset management and valuation services. Dr. Sam Al-Murrani is also Managing Director for Bimini LLC, a privately owned manufacturer of pet dose-form health supplements and health treats.
Dr. Al-Murrani has a B.Sc. in Animal Science from the University of Edinburgh and a Ph.D. in Immunology/Biochemistry from the Roslin Institute and the Department of Veterinary Pathology at the University of Edinburgh. He holds an M.B.A. in Finance from Baker University.
Mike Seely
Phil Austin
Tony Simpson
Aditya Kohli
Doug Sterkel
Matthew Bell
Julia Stephanus
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Samuel Bjork
Alex Loucks
Anders Bendsen Spohr
Michael Helmstetter
Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).
TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.
Michael also serves as Managing Partner of Covenant Animal Health Partners, a TechAccel subsidiary that focuses on development of “revenue-ready” animal health products for both companion and farm animals.
Before founding TechAccel, Michael served as the fifth President and Chief Executive Officer of MRIGlobal – one of the nation's most prominent research institutions. In his 14 years with MRIGlobal (formerly Midwest Research Institute), he led its growth from 2 to 17 national and international locations.
Michael has more than 30 years of experience working with the private sector and government agencies, including laboratory management positions at Applied Marine Research Laboratory in Norfolk, Va., and program management for the Harbor Branch Oceanographic Institution in Fort Pierce, Fla. He was President and Chairman of startup Brevard Teaching and Research Laboratories, a post he held until the company was acquired by MRIGlobal.
Michael received a Ph.D. in Chemical Toxicology/Oceanography from Old Dominion University and a B.S. in Biology from Allegheny College. He has been a panelist, keynote speaker, lecturer, reviewer to several journals, and is the author of numerous publications, articles, book chapters, and technical reports.
He has served on several boards, including Labconco Corp. Board of Directors and University of Missouri-Kansas City Board of Trustees, as well as numerous civic organizations. He is a contributing opinion writer for Forbes.com.
Michael lives in suburban Kansas City.
Email: [email protected]
LinkedIn www.linkedin.com/in/michaelhelmstetter/
John Peryman
Brett Morris
Brett is a Principal for TechAccel LLC, a venture development and technology organization that invests across the agriculture, animal health, and food science industries. Brett leads venture investing and due diligence efforts for the firm and guides all corporate and asset-related transactions.
He also serves as a Partner with Covenant Animal Health Partners LLC, a TechAccel subsidiary dedicated to the development and registration of “revenue-ready” animal health products. Covenant addresses critical market needs across production and companion animals and advances new assets into industry partner portfolios.
Prior to TechAccel, Brett worked in corporate development for a commodity trading and handling company focused in agriculture, feed, and energy. He helped source, evaluate, and execute mergers and acquisitions, equity investments, joint ventures, and organic growth initiatives. Further, he led efforts to assess the Agtech venture capital industry and evaluated startups in several areas including imagery, sensors, trading and logistics, and artificial intelligence. Prior to this, Brett worked for a small strategic advisory firm and a local bank.
Brett serves as a selection committee member for InvestMidwest and the Animal Health Investment Forum and volunteers as a mentor for the Techstars Farm to Fork Accelerator, the Sprint Corporate Accelerator Program and the Ag Innovation Showcase. He also serves as a guest lecturer for the Blue Valley CAPS program.
Brett graduated from the University of Kansas and is a CFA® charterholder. He is a member of the CFA Institute and the Kansas City CFA Society.
Email: [email protected]
LinkedIn https://www.linkedin.com/in/brett-morris-cfa-962a9023/
TechAccel website: www.TechAccel.net
Covenant Animal Health Partners website: www.CovenantAH.net
Jim Allan
Jim has over 20 years’ experience in the animal health industry with Pfizer Animal Health, Zoetis, Merial and Boehringer Ingelheim in product and business development. He has worked on a number of product licensing an M&A projects, divestitures, anti-trust clearances and acted as project manager on the Zoetis IPO from Pfizer. He currently manages business development for Boehringer Ingelheim Animal Health in the US and for its global pet health franchise based in Duluth in Georgia, USA.
Tyre Grant
Todd B. Richter C.F.A
Todd Richter is currently a Senior Managing Director at Guggenheim Partners. His primary focus is on the healthcare services field including managed care/payer services, physician-related businesses and all forms of distribution and outsourcing. In addition, Mr. Richter is responsible for Guggenheim Partners’ coverage of the global animal health field. From 2016 until 2018 Mr. Richter was Vice Chairman of Global Banking at Barclays. From 1999 to 2016 Todd Richter was a Senior Managing Director in the Global Healthcare Corporate & Investment Banking Group at Bank of America Merrill Lynch. From 1981 to 1999, Mr. Richter served as the head of the healthcare services analytical team for Morgan Stanley. Todd Richter earned a B.B.A. in Finance from the College of William & Mary in 1979 and an M.B.A. in Finance with Honors from Indiana University in 1981. Todd was recognized 16 times as a member of the Institutional Investor’s All-America Research Team. He was also listed many times among the Wall Street Journal’s “All-Star” analysts and on the Reuters research poll. Mr. Richter is currently a member of the Board of Directors (Vice Chairman) of Bideawee, one of the nation’s leading animal rescue organizations; a member of the Board of Directors at the Stratton Mountain School (SMS) in Stratton, Vermont, a member of the Board of Directors at Animal Lighthouse Rescue (ALR), and a member of the Dean’s Council for the Kelley School of Business at Indiana University. Finally Mr. Richter is on the Board and faculty of the Columbia University Mailman School of Public Health teaching a course on healthcare consolidation to MPH and MHA candidates.
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
David R. Boyko
David R. Boyko is Director, Global Business Development for Merck Animal Health (known as MSD Animal Health outside the United States and Canada), a part of Merck & Co., Inc., Kenilworth, NJ. In this role, David is responsible to identify, evaluate, negotiate and execute licensing and business development transactions for animal health products and services, including newly emerging animal diseases, biopharmaceuticals, vaccines, drug and vaccine delivery and new, digital technologies. Geographically, he focuses on opportunities for the North American business units.
Underpinning that role are more than twenty years of legal practice, with twenty of those years as a deal lawyer, business partner and counselor in the life sciences industry. His legal career includes extensive experience in corporate development and licensing activities for prescription, over-the-counter health and animal health products and technologies, as well as in the new area of digital health. He has advised executive and senior management levels on a broad range of legal issues, including M&A, regulatory, commercial, corporate governance and litigation, managed lawyers and controlled outside counsel annual budgets in excess of $2MM. David also has been Division Counsel for Healthcare Services & Solutions, Merck's business unit for innovative, non-drug healthcare solutions, a Senior Counsel in the Corporate Transactions Groups of both Merck and Schering-Plough, and an executive officer for Xenogen Corporation. In private practice, David was with the law firms of Wilson Sonsini Goodrich & Rosati and Fried, Frank, Harris, Shriver & Jacobson. He has a number of published articles on intellectual property and antitrust matters, and has chaired licensing panels at several annual meetings of the Association of Corporate Counsel.
David earned his J.D. degree from the University of California Los Angeles, his M.A. degree in International Relations from the University of Southern California and his B.S. degree in Mechanical Engineering from Cornell University. David is also a veteran, having served eight years of active duty as a U.S. Air Force officer.
Headline Partner
Elanco
Website: http://www.elanco.com
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in farm animals and pets in more than 90 countries. With a 65-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life - all to advance the health of animals, people and the planet. Learn more at www.elanco.com.
Associate Partners
TechAccel
Website: http://techaccel.net/
TechAccel, LLC, is a technology and venture development company focused in the agriculture and animal health industry.
Since its founding in 2014, TechAccel sources, invests in and acquires early-stage innovations. Through collaborations with universities and research institutions, TechAccel conducts advancement and de-risking research and development to ready technologies for commercialization.
TechAccel is based in Overland Park, Kansas, with offices in St. Louis, Missouri. For more information, visit www.TechAccel.net. Follow us on Twitter at @Tech_Accel.
Zoetis
Website: http://www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Event Partners
Anterra Capital
Website: http://www.anterracapital.com
We are a specialist venture capital investor dedicated to financing the growth of companies operating in the food & agricultural sectors
We invest across the food supply chain in technology driven companies
We focus on companies headquartered in Europe or North America although we will consider companies in other geographies
At the time of our investment our companies are typically generating revenue and have great growth prospects
We invest up to USD 20m in equity per company taking a significant minority ownership position
We are active in the boards of portfolio companies working alongside management teams to build lasting value
As a sector specialist we pride ourselves on our ability to add value in ways that generalist investors can't even dream of
Argenta
Website: http://www.argentaglobal.com
Argenta Limited, founded in 2006, is the world’s only combined contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. With accredited operations and facilities across New Zealand, the United States and Scotland, Argenta is fully equipped to offer a full range of products and services - from access to innovative intellectual property, formulations research and development (R&D), analytical methods development, clinical trial management through to pilot- technical transfer and commercial-scale manufacturing - to the global animal health industry. Argenta’s 400+ global team develops and exports products and services to over 40 countries.
A privately-owned company headquartered in Auckland, New Zealand, Argenta brings innovation, R&D and manufacturing expertise together in one global company. This makes it ideally placed to accommodate unique product requirements no matter the scale or complexity. Argenta’s facilities in New Zealand, the United States (Iowa, Kansas and New Jersey) and Europe (Scotland) enable the achievement of significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required.
Argenta is honoured to work with a vast range of clients globally - from small and medium-sized enterprises (SMEs) to some of the largest industry players. Argenta has the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies with great ideas to help them find solutions and bring their ideas to fruition.
For more information, please visit www.argentaglobal.com.
Boehringer Ingelheim
Website: http://www.boehringer-ingelheim.com
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information, please visit www.Boehringer-Ingleheim.com
Clinvet
Website: http://www.clinvet.com
Clinvet is a GCP/GLP accredited Contract Research Organisation (CRO) established in 1999 and specialises in the conduct of laboratory and field-based efficacy, safety and metabolism trials for veterinary health products.
Since inception, Clinvet has conducted more than 1300 studies aiding in the discovery, development and registration of veterinary products worldwide.
Services offered by Clinvet
Laboratory in vitro and in vivo efficacy studies as well as safety and metabolism studies for animal medicine. We maintain an extensive bank of parasites (helminths and arthropods) originating from the US, EU and Africa for use in challenges on companion and production animals. Test animals frequently used include rats, rabbits, cats, dogs, goats, sheep, cattle and horses. We offer the following studies:
- Glass vial contact assay
- Artificial membrane feeding assay
- Proof of concept efficacy
- Dose determination and confirmation
- Parasite challenge efficacy
- Bioequivalence
- Pharmacokinetics
- Residue depletion
- Target animal safety
Clinical trial conduct as well as the following support services for animal clinical field and laboratory studies:
- Project management, monitoring and quality assurance
- Protocol, report writing and case report form (CRF) design
- Electronic database, design and validation (EDC/Paper)
- Data management, biostatistics and statistical programming
- Serological (IFA and ELISA) and molecular (qPCR and PCR) diagnostic testing
- Specialised molecular assay development
- Animal genetic profiling, parentage and mutation screening
- Genomic analysis of parasites
For more information, visit www.clinvet.com
Klifovet
Website: http://www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
Solebury Trout
Website: https://soleburytrout.com
Solebury Trout partners with private and public companies across all industries, helping management teams to prepare for capital raising, access investors and tackle complex investor relations and corporate communications issues and opportunities. The company’s deep sector expertise helps clients connect with the audiences who matter most–including investors, analysts, the media, employees and customers. More than 70 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier market access firm serving the life sciences industry. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in the last two years has advised on 25 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country.
Proteon Pharmaceuticals
Website: http://www.proteonpharma.com
PROTEON uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. We have developed products using bacteriophages to control bacterial diseases livestock farming. We have built a platform to develop and deliver solutions prophylactically preventing disease while helping to optimize the microbiome in livestock farming. Our first product BAFASAL, recently launched, prevents (or eliminates) salmonella in poultry.
Series Highlights
The Agenda
You can download our agenda here.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Headline speakers include:
Download Agenda
Venue
Hyatt Regency Boston Harbor, Boston, MA
Venue: Hyatt Regency Boston Harbor
Address: 101 Harborside Drive, Boston, MA 02128
We have arranged a discounted room rate for all event attendees of $239 per night, exclusive of taxes
To make your reservations, please click here
If you need additional assistance, please contact the hotel Reservation Department on +1 877-803-7534 or click here to find contact information by Region.
Please book by 9th March 2019 - after this rates are subject to availability.
If the group rate is no longer available, prevailing rates may be offered for some or all of your dates.
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
- Please note that a $70 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in USD
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
Advisory Board
Clinton Lewis
Joachim Hasenmaier
Dirk Ehle
George Gunn
Linda Rhodes
Aaron Schacht
Alan Mackay
Dr. James Lloyd
Sébastien Huron
Jean Deleforge
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
